Morguard Corp

SUPREMO Trial Shows Chest Wall Radiation May Be Omitted in Intermediate-Risk Breast Cancer Without Compromising Survival

- The international SUPREMO trial found no significant difference in 10-year overall survival between breast cancer patients who received postmastectomy chest wall irradiation versus those who did not (81.4% vs 81.9%). - Among 1,607 women with intermediate-risk early breast cancer, chest wall recurrence occurred in only 1.1% of irradiated patients versus 2.5% of non-irradiated patients, representing less than 2 percentage points difference. - The findings suggest modern systemic therapies may provide sufficient disease control, potentially allowing radiation therapy to be omitted in certain intermediate-risk patients. - This paradigm shift emphasizes the growing importance of pharmacologic optimization and multidisciplinary care in breast cancer treatment strategies.